Tanabe Report issue

For profit Phase 1 Phase 3
Founded: Tokyo Japan (1901)
Status: Acquired by Mitsubishi Tanabe (1999)

Organization Overview

First Clinical Trial
2014
NCT02269475
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Tanabe Pediatrics Clinic | Tanabe Research Laboratories | Tanabe Research Laboratories USA Inc

Active Ingredients

Drugs in Phase 3 Trials (1)

live attenuated influenza virus vaccine (Flumist) (1 trial)

Drugs in Phase 1 Trials (1)

tr1801-adc (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2